Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
5/20/2013 1:50:18 PM
More...
|
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
5/20/2013 10:44:34 AM
More...
|
Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Lower GI Functional Disorders
4/16/2013 9:40:51 AM
More...
|
Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity
1/4/2013 9:32:23 AM
More...
|
Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Inc. (PFE) Ventures as an Investor
11/27/2012 6:37:45 AM
More...
|
Rhythm Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131
10/22/2012 9:39:09 AM
More...
|
Rhythm Drums Up $25 Million to Advance Diabetes and Obesity Drugs
6/13/2012 7:20:50 AM
More...
|
Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
6/6/2012 11:09:27 AM
More...
|
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
5/22/2012 12:22:17 PM
More...
|
Rhythm Names Lex Van der Ploeg Chief Scientific Officer
11/30/2011 11:22:04 AM
More...
|
|